Cerulean's CRLX101 misses OS endpoint in NSCLC trial

Cerulean Pharma Inc. (Cambridge, Mass.) said CRLX101 given every other week plus best supportive care missed the primary endpoint of improving median overall survival (OS) vs. best supportive care alone in a Phase IIb trial to treat advanced non-small cell lung cancer (NSCLC). The open-label, Russian and Ukrainian trial enrolled 157 patients who progressed after one to two regimens of chemotherapy. Cerulean declined to disclose details. The company said it will focus on its other cancer programs for CRLX101 instead of continuing research in NSCLC. ...